Browse the evidence

Obesity is associated with disturbed serotonergic signaling, specifically decreased central serotonin release and altered receptor availability, which may contribute to the failure to suppress food intake.

In obesity, the brain's serotonin system often becomes less sensitive or releases less serotonin, making it harder to feel full. This biological change can drive overeating. Treatments that target this system (like certain drugs) may help restore this signaling.

Selective serotonin reuptake inhibitors (SSRIs) are associated with an increased risk of long-term weight gain, contrasting with their short-term anorexigenic effects.

If you take SSRIs, be aware they may contribute to weight gain over time. Talk to your doctor about monitoring your weight and discussing alternative treatments if this is a concern.

During the post-ovulatory luteal phase (LP) of the menstrual cycle, elevated progesterone levels increase core body temperature and reduce the nocturnal decline in body temperature, which contributes to subjective sleep disturbances and altered sleep architecture (specifically reduced REM sleep and increased spindle frequency activity) in healthy women.

If you are a healthy woman, expect your sleep architecture to change during the week before your period. You may experience less deep REM sleep and more sleep spindles due to a natural rise in body temperature driven by progesterone. This is a normal physiological shift, not a failure of your sleep hygiene. If you suffer from severe mood or sleep symptoms (PMDD), chronotherapeutic methods to realign circadian rhythms may help.

Nutrient deprivation (fasting or calorie restriction) increases SIRT6 protein levels in specific tissues (brain, kidney, heart, adipose) by stabilizing the protein via reduced proteasomal degradation, rather than by increasing transcription.

Fasting and calorie restriction do more than just burn calories; they actively stabilize specific proteins like SIRT6 in key organs (brain, heart, fat). This stabilization is a biological response to nutrient scarcity, potentially contributing to the health benefits associated with fasting, such as improved metabolic function and genome stability.

p53 positively regulates SIRT6 protein levels under normal growth conditions but is not required for the nutrient-dependent stabilization of SIRT6 during fasting.

Under normal eating conditions, the protein p53 helps maintain baseline levels of SIRT6. However, when you fast, your body uses a different mechanism to boost SIRT6 that doesn't rely on p53, suggesting multiple layers of protection.

Testosterone supplementation reverses age-related sarcopenia in mice by suppressing processed myostatin and JNK activation while stimulating Akt and Notch signaling pathways.

For aging individuals experiencing muscle loss, testosterone therapy may be a viable option to restore muscle mass and strength, particularly when combined with lifestyle interventions. Consultation with a healthcare provider is essential to determine suitability and monitor for potential side effects.

Activation of the CML-RAGE axis in adipose tissue drives obesity-associated inflammation and insulin resistance by dysregulating adipokine expression (increasing pro-inflammatory cytokines and decreasing adiponectin).

This research suggests that obesity-related insulin resistance is driven by a specific molecular loop involving CML and RAGE in fat tissue. While this paper does not prescribe a direct intervention, it implies that reducing the formation of CML (an advanced glycation end product formed via lipid peroxidation) or blocking RAGE could theoretically improve insulin sensitivity. For now, strategies that reduce oxidative stress and lipid peroxidation (often associated with high sugar/fat diets) may indirectly mitigate this pathway.

Obese individuals exhibit significantly lower plasma CML levels compared to lean individuals, a phenomenon attributed to the trapping of CML in adipose tissue via RAGE.

Standard blood tests for CML (a marker of glycation/oxidative stress) may underestimate the total body burden of these compounds in obese individuals because the compounds are trapped in fat tissue. This trapping mechanism contributes to local inflammation and insulin resistance. Weight loss (bariatric surgery) was shown to increase plasma CML, suggesting that reducing fat mass releases this trapped burden back into circulation.

Gut microbiota dysbiosis and subsequent bacterial translocation of lipopolysaccharides (LPS) into systemic circulation cause metabolic endotoxemia, which triggers chronic low-grade inflammation and insulin resistance.

If you have obesity or type 2 diabetes, your gut bacteria may be leaking inflammatory substances (LPS) into your bloodstream, causing insulin resistance. Focus on improving gut health through diet (e.g., fiber, prebiotics) to reduce this 'leaky gut' effect and lower systemic inflammation.

In normogonadal men, low plasma levels of free testosterone and SHBG do not independently predict insulin resistance, beta-cell dysfunction, or hepatic glucose output; their association with metabolic risk is mediated entirely by adiposity.

For men with normal testosterone levels, low T is not the independent cause of insulin resistance. The observed link between low T and metabolic risk is driven by obesity, particularly truncal fat. Focusing on reducing abdominal adiposity is more effective for improving insulin sensitivity than attempting to raise testosterone levels through therapy, provided baseline levels are normal.

In normogonadal men, lower plasma bioavailable testosterone levels are predictive of greater fat deposition in subcutaneous truncal and peripheral adipose tissues.

In men with normal testosterone, lower levels within the normal range are associated with higher subcutaneous fat, especially around the trunk. This suggests that maintaining healthy testosterone levels may help manage body fat distribution, although it is not the sole determinant of insulin resistance.

DNA methylation levels in blood are significantly associated with specific blood serum metabolic traits (metabotypes), independent of underlying genetic variants, suggesting epigenetic regulation of human metabolism.

This research highlights that your metabolic health is not just written in your DNA sequence but is also regulated by epigenetic marks (DNA methylation) influenced by your lifestyle and environment. While this study doesn't prescribe a specific diet or exercise, it underscores the importance of lifestyle factors (like smoking cessation, noted as a driver for some associations) in maintaining healthy metabolic profiles through epigenetic regulation.

Shorter leukocyte telomere length (LTL) is associated with a significantly higher risk of all-cause mortality and cardiovascular disease (CVD).

Your blood test's telomere length isn't a destiny, but a status report. Shorter telomeres correlate with higher heart disease and mortality risk. You can influence this trajectory by managing stress, exercising regularly, maintaining a healthy weight, and avoiding smoking, as these factors are linked to slower telomere shortening.

Spexin gene expression and circulating levels are significantly down-regulated in obese human adipose tissue and serum compared to non-obese individuals.

In obese humans, the body produces significantly less of the peptide Spexin in fat tissue and blood compared to lean people. This deficiency is correlated with higher levels of Leptin and increased fat uptake, suggesting that Spexin plays a role in preventing obesity.

The human energy homeostatic system is evolutionarily biased towards weight gain and fat storage, making long-term weight loss difficult to achieve through diet and exercise alone.

Understand that your body is designed to regain lost weight. This is not a moral failing but a biological reality driven by hormones like leptin and neuropeptide Y. Long-term success often requires addressing these hormonal drivers, potentially through medical interventions, rather than relying solely on willpower.

Leptin resistance in common obesity prevents the hormone from signaling satiety to the brain, rendering high circulating levels ineffective for weight loss.

In common obesity, your body produces plenty of leptin, but your brain doesn't hear it. This 'leptin resistance' is a key barrier. Treatments that simply add leptin have largely failed; effective strategies must overcome this resistance.

Neuropeptide Y (NPY) and Agouti-Related Protein (AGRP) are potent orexigenic peptides that increase food intake and decrease energy expenditure, particularly when leptin signaling is low.

When you are in a caloric deficit, your body increases NPY and AGRP to make you hungry and slow your metabolism. This is a normal survival mechanism.

Alpha-melanocyte-stimulating hormone (α-MSH) and Cocaine- and Amphetamine-Regulated Transcript (CART) reduce food intake and increase energy expenditure, acting as counter-regulatory peptides to NPY and AGRP.

α-MSH and CART help you feel full and burn energy. In obesity, these signals are often suppressed.

High-fat diet exposure causes reduced hypothalamic mTORC1 signaling, which contributes to leptin resistance and diet-induced obesity.

This research suggests that chronic high-fat intake disrupts a specific brain signaling pathway (mTORC1) that tells your brain you are full. This disruption leads to resistance to the hormone leptin, making it harder to regulate appetite. While this is a rodent study, it implies that dietary composition (specifically fat content) directly impacts brain signaling mechanisms that control hunger and weight.

CNTF analog CNTFAx15 can induce anorexia and activate mTORC1 signaling even in states of leptin resistance caused by high-fat diets.

This study shows that a specific cytokine analog (CNTFAx15) can reduce food intake in obese animals even when they are resistant to the natural hormone leptin. This suggests that targeting specific brain pathways (like mTORC1) might be a viable strategy for treating obesity where standard hormonal signals fail.

Historical weight-loss drugs (Thyroid hormones, DNP, Amphetamines) failed due to narrow therapeutic windows and severe adverse effects, despite some efficacy.

Historical weight-loss drugs like DNP, thyroid extracts, and amphetamines were largely withdrawn or restricted due to severe side effects (cataracts, heart issues, addiction) and limited efficacy (<10% weight loss). Their failure highlights the need for safer, more effective modern therapies like polyagonists.

Flavin Monooxygenase 3 (FMO3) activity promotes dyslipidemia and atherosclerosis by regulating hepatic lipogenesis, gluconeogenesis, and impairing transintestinal cholesterol export (TICE).

FMO3 is an enzyme that not only processes nutrients into TMAO but also directly regulates how your liver handles fats and sugars. High FMO3 activity is linked to worse lipid profiles and increased atherosclerosis risk. This regulation happens through complex gene signaling (FXR, LXR, PPARa) that controls cholesterol export and fat storage.

Lower morning urinary cortisol levels are associated with greater difficulty getting to sleep (sleep onset latency) during the menopausal transition, challenging the assumption that high stress/cortisol always correlates with worse sleep onset.

If you have trouble falling asleep, don't just assume it's 'high stress.' This research suggests that lower cortisol levels might actually be linked to sleep onset issues in some women. Focus on calming cognitive arousal and managing hot flashes rather than just trying to lower stress hormones.

Low serum levels of IGF-I are associated with the severity of NAFLD, including inflammation, hepatocyte ballooning, and fibrosis, even in non-GHD patients.

If you have NAFLD, your IGF-I levels might be low, which correlates with more severe liver damage. While this doesn't mean you should take IGF-I supplements (which are not standard), it highlights the importance of the GH-IGF-I axis in liver health.